Eli Lilly and Company

Kumiko Takeuchi

Daniel Jon Sall

Gerald Floyd Smith

Ho-Shen Lin

Minsheng Zhang

Richard Waltz Harper

Jefferson Ray McCowan

Matthew Joseph Fisher

Alan David Palkowitz

Nickolay Y Chirgadze

Todd Jonathan Kohn

Jolie Anne Bastian

Michael Robert Wiley

Michael Enrico Richett

Robert J Foglesong

Mary George Johnson

Michael Lyle Denney

Michael P Lynch

Vincent Patrick Rocco

Patrick Gianpietro Spinazze

John Xiaoqiang He

Nicholas Allan Honigschmidt

Valentine Joseph Klimkowski

Russell Dean Stucky

Joseph A Jakubowski

Jennifer Marie Tinsley

Dale Eugene Mais

Jon Kevin Reel

Charles Howard Mitch

Winston S Marshall

Richard L Simon

Mitchell I Steinberg

Celia A Whitesitt

Shawn Christopher Miller

Kenneth Lee Hauser

Miles Goodman Siegel

Sherryl L Lifer

William Pfeifer

K Jeff Thrasher

Donald B Boyd

Nicholas J Bach

Michael R Jirousek

Theo Schotten

Wolfgang Stenzel

Jeffry Bernard Franciskovich

John E Toth

Michael Paal

Edward C R Smith

Sean Patrick Hollinshead

Marvin M Hansen

Nuria Diaz Buezo

Jeffrey Thomas Mullaney

Steven Lee Kuklish

Concepcion Pedregal-Tercero

Gerd Ruhter

Daniel James Koch

Ana Belen Bueno Melendo

Maria-Jesus Blanco-Pillado

Bin Liu

Mark Donald Chappell

William Glen Holloway

Steven James Quimby

Dana Rae Benesh

Ryan Thomas Backer

David Gene Barrett

Chad Nolan Wolfe

Marta Garcia De La Torre

Maria Jesus Blanco-Pillado

James Edward Matt

Dana Rae Smith

Elizabeth Marie Thomas

Jolie Ann Bastian

Todd Johnathan Kohn

James Erwin Fritz

James Edward Junior Matt

GPR119 agonist compounds of the formula: and pharmaceutical compositions for the treatment of diabetes and obesity.

GPR119 agonists

A compound of the formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate, diasteromers or mixtures thereof, or a solvate thereof, formulations and methods of use thereof, as opioid receptor antagonists are disclosed wherein the variables are as described herein. 

6-substituted nicotinamide derivatives as opioid receptor antagonists

This application relates to a substituted carboxamide compound of formula I, or a pharmaceutically acceptable salt thereof, as defined herein, a pharmaceutical composition thereof, and its use in treating pain.

Substituted carboxamides

A compound of the formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate, diastereomers or mixtures thereof, or a solvate thereof, formulations and methods of use thereof, as opioid receptor antagonists are disclosed wherein the variables are as described herein. 

A compound of the formula I: (I) wherein the variables are as described herein, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixture thereof, formulations and methods of use thereof are disclosed. 

Opioid receptor antagonists

A compound of the formula (I) wherein the variables Xto X, Rto Rincluding R, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed 

Diaryl ethers as opioid receptor antagonist

The present invention provides compounds of formula (I): which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine. 

Indole derivatives for the treatment of depression and anxiety

The present invention provides compounds of formula (I) which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine

Benzofuran derivatives

The present invention provides compounds of formula (I) which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.

Tropane linked benzofuran derivatives

The present invention provides compounds of formula (I): which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.

Piperidines derivatives and their use as serotonin receptor antagonists

This application relates to novel compounds of formula (I) (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of defined compounds of formula (I) as thrombin inhibitors.

Antithrombotic agents

The invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts, as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of the compounds of formula (I) as thrombin inhibitors.

This invention relates to certain novel imidazoline compounds and analogues thereof, to their use for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present, to pharmaceutical compositions comprising them, and to processes for their preparation.

Hypoglycemic imidazoline compounds

This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of defined compounds of formula I as thrombin inhibitors.

Thrombin inhibitors

This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of the compounds of formula I as thrombin inhibitors.

Growing community of inventors

Indianapolis, IN, United States of America

Kumiko Takeuchi